IBXXF Company Profile and Key Details

Q: Who are the executives of IBXXF?

Dr. Yalia Jayalakshmi Ph.D.Chief Devel. OfficerMr. Geoff HollisChief Financial Officer & Company Sec.Mr. Geoff Hollis AGIA, BComm, CAChief Financial Officer & Company Sec.Dr. Isaac J. Bright M.D.MD & Chief Executive Officer

PNK : IBXXF

Imagion Biosystems

$0.26

0.232+966.67%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Imagion Biosystems Limited (IBXXF) stock declined over -50.00%, trading at $0.02 on OTC, down from the previous close of $0.03. The stock opened at $0.02, fluctuating between $0.02 and $0.02 in the recent session.

Stock Snapshot

0.03

Prev. Close

3.31M

Market Cap

0.015

Day Low

-1.46

P/E Ratio

-0.01028

EPS (TTM)

-0.01

Cash Flow per Share

0.02

Open

220.89M

Number of Shares

0.015

Day High

3,285.89%

Free Float in %

Book Value

30K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 30, 2026	0.03	0.03	0.03	0.03	3K
Apr 14, 2026	0.01	0.01	0.01	0.01	2.5K
Mar 31, 2026	0.01	0.01	0.01	0.01	1.8K
Mar 19, 2026	0.02	0.02	0.02	0.02	30K
Mar 18, 2026	0.04	0.04	0.02	0.02	23.8K
Mar 17, 2026	0.02	0.02	0.02	0.02	327
Mar 06, 2026	0.02	0.02	0.02	0.02	90K
Feb 26, 2026	0.01	0.01	0.01	0.01	100
Nov 25, 2025	0.01	0.01	0.01	0.01	1.95K
Nov 03, 2025	0.01	0.01	0.01	0.01	1.25K
Oct 15, 2025	0.03	0.03	0.03	0.03	175K
Sep 18, 2025	0.02	0.02	0.02	0.02	0
Sep 15, 2025	0.02	0.02	0.02	0.02	100K
Sep 11, 2025	0.02	0.02	0.02	0.02	0
Sep 08, 2025	0.02	0.02	0.02	0.02	0
Sep 04, 2025	0.02	0.02	0.02	0.02	5K
Sep 02, 2025	0.02	0.02	0.02	0.02	100K
Aug 26, 2025	0.02	0.02	0.02	0.02	0
Aug 22, 2025	0.02	0.02	0.02	0.02	100K
Aug 20, 2025	0.02	0.02	0.02	0.02	163.55K

Contact Details

Melbourne, VIC 3000

Australia

https://imagionbiosystems.com 855 564 5264

About Company

Imagion Biosystems Limited is dedicated to advancing medical imaging through innovative technologies centered on superparamagnetic relaxometry. The company's core mission is to enable the early detection of diseases, with a particular focus on cancer, and to monitor the efficacy of therapeutic interventions. Its operational scope encompasses nanotechnology, biotechnology, and cancer diagnostics, all built upon its proprietary superparamagnetic relaxometry platform. Imagion's product pipeline includes MagSense, which is currently undergoing Phase I clinical trials for its application in HER2-positive breast cancer detection and management, as well as PrecisionMRX, an iron oxide nanoparticle engineered for general cancer detection. Imagion Biosystems also fosters strategic alliances, including a collaborative research program with Patrys Limited designed to integrate their respective technologies for improved imaging and diagnosis of brain tumors. Additionally, the company has a joint development agreement with Global Cancer Technology, Inc. to further develop GCT's novel nanoscintillator technology for the therapeutic treatment of breast cancer. The company was founded in 2016 and is headquartered in San Diego, California.

Stock Peers

LZAGF

-5-0.92%

Lonza Group AG$541.00 ERFSF

Eurofins Scientific SE$60.50 OPGN

9.75+64.36%

OpGen, Inc.$23.91 SKHHY

-0.03-0.18%

Sonic Healthcare Limited$16.77 SKHCF

Sonic Healthcare Limited$16.20 WUXAY

0.04+0.87%

WuXi AppTec Co., Ltd.$4.62 PCHM

PharmChem, Inc.$3.13 ANPCY

ANGLE plc$2.39 IDXG

-0.11-8.03%

Interpace Biosciences, Inc.$1.26 IDGXF

0.012+4.05%

Integrated Diagnostics Holdings plc$0.31

Company Overview

Imagion Biosystems Limited (OTC:IBXXF) closed at $0.01 USD, losing -$0.01 (-50.00%) from the previous close of $0.03. The stock is currently mid-range between its 52-week high and low $0.01 and $0.04. With a market capitalization of about $3.31 million, Imagion Biosystems Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 3.00 thousand shares, trading with heavier-than-usual volume. Headquartered in Melbourne, VIC, Imagion Biosystems Limited operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Robert Romeo Proulx, the company employs approximately 11 people and listed since September 21, 2020. Imagion Biosystems Limited is dedicated to advancing medical imaging through innovative technologies centered on superparamagnetic relaxometry.

Valuation Metrics

Imagion Biosystems Limited trades at a P/E ratio of -1.38, slightly below the S&P 500 average, with a price-to-sales ratio of 184.51 and a price-to-book ratio of -3.62 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.17, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Financial & Profitability Overview

Over the trailing twelve months, Imagion Biosystems generated $473.43K in revenue, or $0.00 per share. Gross margin was 100.00%, operating margin -2071.11%, and net profit margin -2071.53%. Returns are negative, with ROA at -98.31% and ROE at -209.67%.
On valuation metrics, Imagion Biosystems trades at a P/E of -1.38, P/S of 184.51 and P/B of -3.62. Liquidity is tight, with a current ratio of 0.48 and quick ratio of 0.48. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -223.10 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.19, supported by a cash flow-to-debt ratio of -1.58.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Imagion Biosystems posted revenue of $473.43K, down slightly from $232.87K in the prior quarter. Gross profit was $473.43K (margin 100.00%). Operating income was - $9.81M (margin -2071.1%). Net income was- $9.81M (EPS - $0.01).
The company ended the quarter with $4.45M in cash and short-term investments, a total debt of $4.60M, and net debt of $158.27K. Total assets were $9.98M, with equity of $0.00. Financials further reflected weakness, with operating cash flow of $0.00, free cash flow of - $507.32K, and capital expenditures of - $507.32K.

Price Forecast & Outlook

Our AI price prediction model suggests that Imagion Biosystems Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Imagion Biosystems Limited trading at a premium to the broader market with a P/E of -1.38.

Frequently Asked Questions

What is the current Imagion Biosystems Limited (IBXXF) stock price?

Imagion Biosystems Limited (OTC: IBXXF) stock price is $0.02 in the last trading session. During the trading session, IBXXF stock reached the peak price of $0.02 while $0.02 was the lowest point it dropped to. The percentage change in IBXXF stock occurred in the recent session was -50% while the dollar amount for the price change in IBXXF stock was - $0.02.

IBXXF's industry and sector of operation?

The OTC listed IBXXF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Imagion Biosystems Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IBXXF?

Dr. Yalia Jayalakshmi Ph.D.
Chief Devel. Officer
Mr. Geoff Hollis
Chief Financial Officer & Company Sec.
Mr. Geoff Hollis AGIA, BComm, CA
Chief Financial Officer & Company Sec.
Dr. Isaac J. Bright M.D.
MD & Chief Executive Officer

How IBXXF did perform over past 52-week?

IBXXF's closing price is 45.45% higher than its 52-week low of $0.01 where as its distance from 52-week high of $0.04 is -82.17%.

How many employees does IBXXF have?

Number of IBXXF employees currently stands at 11.

Link for IBXXF official website?

Official Website of IBXXF is: https://imagionbiosystems.com

How do I contact IBXXF?

IBXXF could be contacted at phone 855 564 5264 and can also be accessed through its website. IBXXF operates from Suite 2, Melbourne, VIC 3000, Australia.

How many shares of IBXXF are traded daily?

IBXXF stock volume for the day was 30K shares. The average number of IBXXF shares traded daily for last 3 months was 3K.

What is the market cap of IBXXF currently?

The market value of IBXXF currently stands at $3.31M with its latest stock price at $0.02 and 220.89M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	11
Beta	-0.21
Sales or Revenue	$473.43K
5Y Sales Change%	53.885%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

IBXXF Company Profile and Key Details

Imagion Biosystems

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics